Categories: AnalystsLife Sciences

Centric Health is a Buy, says Byron Capital’s Douglas Loe

Ontario Premier Dalton McGuinty meets Daniel Carriere, President and CEO of Centric Health, after the company acquired Motion Specialties in February 2012.
Centric Health (TSX:CHH) today reported its Q1, 2012 results. Due mostly to what the company calls “seven notable acquisitions ” revenue was up a whopping 353% to to $104.3-million from $23.0-million in the prior-year.

The company’s bottom line improved, too. Adjusted EBITDA increased 350% to $11.7-million from the $2.2-million the company reported in Q1 2011.

Byron Capital Healthcare analyst Douglas Loe says that although Centric’s margins grew to 11.2% from 8.1% in Q4, they remain below the industry average of 12.5% to 13%, and well below the 15% margins Loe expects the company to post by the second half of 2013. Still, the Byron analyst believes that the numbers are solid, considering the feverish pace of Centric’s acquisition spree. In a research update to clients today, Loe Maintain BUY rating and $2.00 target price.

_

This story is brought to you by Agrimarine (TSXV:FSH). Not all salmon farms are the same. Click here to learn how Agrimarine is meeting consumer demand for sustainable aquaculture.

__

Founded in 2001, Toronto’s Centric Health provides a range of healthcare services including medical assessments, rehabilitation management and physiotherapy. The company has quietly become a player in the Canadian healthcare services field, having grown its revenue from $15.7-million in fiscal 2008 to more than $200-million in 2011. The physiotherapy market has become a focus for Centric. In Q1 alone, the The company expanded its national physiotherapy footprint through the acquisition of five physiotherapy businesses.

Loe says physiotherapy, having generated $45.1 million in revenue at a 15.5% margin, is a bright spot for Centric. The company’s performance in that area, he says, is covering for softer margins in the company’s surgical and medical centers, and in pharmacy.

Share of Centric Health closed today down 5% to $1.13.

___________________________________________________________________________________________________________________

___________________________________________________________________________________________________________________

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: chh
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

6 hours ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

13 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

13 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

14 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

1 day ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

1 day ago